Pfizer posts strong Q2 earnings and raises EPS outlook, with oncology growth and new drugs offsetting looming headwinds.

Counterfeit Medicine is a growing global threat. At Pfizer, a dedicated team is leading the fight to stop these dangerous fakes. CT Buzz reporter Jillian Andrews visited Pfizer’s Connecticut ...

Pfizer delivered a strong Q2 earnings beat, raising FY2025 guidance and demonstrating effective cost-cutting. Learn why PFE ...

Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...

Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...

Progressive stays No. 1 in radio ad rankings for August 4–10, as Pfizer leaps into the top 5 and Lenovo returns for ...

Chief Executive Albert Bourla told analysts he is hopeful about finding a solution in response to President Trump’s demands.

The Score is a weekly review of the biggest stock moves and the news that drove them. Here is this week's installment: ...

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

Pfizer introduces its next-gen 20-valent pneumococcal conjugate vaccine (PCV20) in India for adult immunization against 20 ...

Pfizer beats Q2 2025 estimates, raises EPS guidance, boasts a 7%+ dividend yield, yet faces patent and pricing risks. See why ...

Pfizer CEO Albert Bourla is expected at a pro-Trump fundraiser on Friday, sources told CBS News, one day after the president ...